Business Segments · Revenue
Reportable Segment — Revenue
Eli Lilly Reportable Segment — Revenue increased by 2.6% to $19.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 55.5%, from $12.73B to $19.80B. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Revenue shows an upward trend with a 31.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful product adoption and market expansion, while a decrease suggests potential loss of market share or pricing pressure.
Detailed definition
Represents the total gross inflow of economic benefits arising from the ordinary operating activities of the reportable...
Peer comparison
Comparable to net sales or segment revenue reported by other large-cap pharmaceutical companies.
Metric ID:
lly_segment_reportable_segment_revenueHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.14B | $7.14B | $7.14B | $7.14B | $8.53B | $8.53B | $8.53B | $8.53B | $8.77B | $11.30B | $11.44B | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +19.6% | +0.0% | +0.0% | +0.0% | +2.8% | +28.9% | +1.2% | +18.3% | -5.9% | +22.2% | +13.1% | +9.6% | +2.6% |
| YoY Change | — | — | — | — | +19.6% | +19.6% | +19.6% | +19.6% | +2.8% | +32.5% | +34.1% | +58.6% | +45.2% | +37.6% | +53.9% | +42.6% | +55.5% |
Range$7.14B – $19.80B
CAGR+29.1%
Avg YoY Growth+33.9%
Median YoY Growth+34.1%
Current Streak4 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's reportable segment — revenue?
- Eli Lilly (LLY) reported reportable segment — revenue of $19.80B in Q1 2026.
- How has Eli Lilly's reportable segment — revenue changed year-over-year?
- Eli Lilly's reportable segment — revenue increased by 55.5% year-over-year, from $12.73B to $19.80B.
- What is the long-term trend for Eli Lilly's reportable segment — revenue?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — revenue has grown at a 31.7% compound annual growth rate (CAGR), from $28.54B to $65.18B.
- What does reportable segment — revenue mean?
- The total sales generated by this specific business segment.